|May 28, 2014|
|07:47 EDT||MYGN, LH||Myriad Genetics participation pacts to be terminated by NJ Horizon Blue Cross|
Horizon Blue Cross Blue Shield of New Jersey, an independent licensee of the Blue Cross and Blue Shield Association, announced yesterday that it is terminating its participation agreements with Myriad Genetics (MYGN), effective June 15 for patients enrolled in Horizon BCBSNJ managed care plans and effective July 3 for patients enrolled in Horizon BCBSNJ PPO and Indemnity plans. Following the terminations of Myriad Genetics, LabCorp (LH) will be the only participating clinical laboratory to provide BRCA-specific genetic testing for Horizon BCBSNJ patients, the insurer noted. Reference Link
News For MYGN;LH From The Last 14 Days
|October 20, 2014|
|08:45 EDT||LH||LabCorp launches HIV GenoSure Archive|
Laboratory Corporation of America Holdings and Monogram Biosciences, Inc., part of the LabCorp Specialty Testing Group, today announced the launch of HIV GenoSure Archive, the first laboratory test to help optimize antiretroviral drug regimens in virally suppressed HIV patients. GenoSure Archive was developed using the Next Generation Sequencing platform.
|October 17, 2014|
|12:52 EDT||MYGN||On The Fly: Midday Wrap|
Stocks on Wall Street were sharply higher at midday, as the averages bounce back following steep declines in several recent sessions. Better than expected earnings from General Electric (GE) and Morgan Stanley (MS), a rebound in European stock markets and a stronger than expected reading on U.S. consumer confidence may all be contributing to the brightened mood evidenced by today's trading. ECONOMIC EVENTS: In the U.S., housing starts rebounded 6.3% to a 1.017M pace in September, beating expectations for a monthly increase of 4.6%. Building permits increased 1.5% to a 1.018M rate, which was below the expected 2.3% rise. The first release on the University of Michigan's consumer sentiment index for October came in at 86.4, versus expectations for a decline to 84.0 from the prior 84.6 reading. COMPANY NEWS: General Electric shares rose over 3% after the company reported better than expected third quarter profit and nearly in-line revenues. Morgan Stanley, whose quarterly results also topped Street expectations, advanced 2.5%. MAJOR MOVERS: Among the notable gainers was Westmoreland Coal (WLB), which gained 23% after it stuck a deal to acquire Oxford GP, the general partner of Oxford Resource Partners (OXF), and contribute certain royalty bearing coal reserves to Oxford in return for Oxford common units. Afterward, Brean Capital raised its price target on Westmoreland to $60, noting the announcement represents an entry into the MLP space. Also higher were shares of Textron (TXT), which advanced 11% after the aircraft and defense company reported better than expected third quarter earnings per share and raised its profit outlook for fiscal 2014. Among the noteworthy losers was Urban Outfitters (URBN), which dropped 13% and was downgraded by at least three Street research firms after the owner of Anthropologie and its namesake clothing stores warned that its Q3 earnings may be negatively impacted by continued weakness in its comparable retail sales. Also lower was Myriad Genetics (MYGN), which fell 7% after guiding to lower than expected Q1 adjusted earnings, citing a higher than expected increase in costs to perform its myRisk Hereditary Cancer test following the test's national launch. INDEXES: Near midday, the Dow was up 295.34, or 1.83%, to 16,412.58, the Nasdaq was up 62.43, or 1.48%, to 4,279.82, and the S&P 500 was up 29.48, or 1.58%, to 1,892.24.
|07:16 EDT||MYGN||Myriad Genetics receives draft medicare coverage for Prolaris|
Myriad Genetics announced that Palmetto GBA, a Medicare Administrative Contractor, or MAC, that assesses molecular diagnostic technologies, has issued a draft local coverage determination, or LCD, for Prolaris, Myriad's prostate cancer test. The LCD is posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services, or CMS, website and establishes the coverage policy for Medicare beneficiaries. The current language in the draft LCD provides reimbursement coverage for the approximately 50% of prostate cancer patients defined as low and very low risk. Under Medicare rules, the draft LCD is subject to a minimum 45-day public comment period. After comments are considered, a final LCD is issued, which goes into effect after a minimum 45-day notification period.
|07:14 EDT||MYGN||Myriad Genetics sees FY15 EPS $1.90-$2.00, consensus $1.93|
Backs FY15 revenue guidance of $800M-$820M, consensus 804.15M.
|07:14 EDT||MYGN||Myriad Genetics sees Q1 adjusted EPS 25c, consensus 41c|
Subscribe for More Information
|07:00 EDT||MYGN||Myriad Genetics trading halted, pending news|
Subscribe for More Information
|October 15, 2014|
|19:16 EDT||LH||LabCorp acquisition of LipoScience clears antitrust approval|
Laboratory Corporation of America Holdings, or LabCorp (LH), announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (LPDX) by LabCorp. The transaction is expected to close in Q4.
|16:11 EDT||LH||LabCorp's LipoScience acquisition clears antitrust approval |
LipoScience (LPDX) announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience by Laboratory Corporation of America Holdings (LH). The transaction remains subject to other customary closing conditions set forth in the Agreement and Plan of Merger, dated September 24. The transaction is expected to close in Q4.
|October 9, 2014|
|14:54 EDT||MYGN||Capital World Investors reports 10.5% passive stake in Myriad Genetics |